BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//UCLA - ECPv5.14.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UCLA
X-ORIGINAL-URL:https://www.chemistry.ucla.edu
X-WR-CALDESC:Events for UCLA
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220310T120000
DTEND;TZID=America/Los_Angeles:20220310T120000
DTSTAMP:20260614T165930
CREATED:20220304T062605Z
LAST-MODIFIED:20220304T062605Z
UID:13615-1646913600-1646913600@www.chemistry.ucla.edu
SUMMARY:Chem 218: Student Exit Seminar
DESCRIPTION:“Choosing the right lens: Energy surfaces and chemical identity in the photodissociation of Na2+ in different solvent environments”
URL:https://www.chemistry.ucla.edu/seminars/chem-218-student-exit-seminar/
CATEGORIES:Other,Seminars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220310T160000
DTEND;TZID=America/Los_Angeles:20220310T160000
DTSTAMP:20260614T165930
CREATED:20220302T044201Z
LAST-MODIFIED:20220302T044201Z
UID:13613-1646928000-1646928000@www.chemistry.ucla.edu
SUMMARY:Special Organic Colloquium - Prof. Herman O. Sintim
DESCRIPTION:Novel chemotypes of kinase inhibitors for the potential treatment of recurrent cancers \nAbstract: Therapeutic resistance remains a critical issue in cancer treatment. While cancer patients who harbor dysregulated protein kinases benefit from the use of kinase inhibitors (KIs)\, many fail therapy and almost all patients become resistant to treatment\, indicating a critical unmet need to prevent treatment failure.  \nThus far (as of December 2021)\, the FDA has approved 69 protein kinase inhibitors and several others are also in various stages of clinical trials. Although many compounds that inhibit protein kinases have been described in the literature\, only a small region of the chemical space has been explored for protein kinase inhibition and the majority of FDA approved kinase inhibitors contain only a handful of core moieties\, such as indazole\, quinoline\, isoquinoline\, quinazoline\, pyrazole and pyrimidine. To belabor this point\, about ~20% of FDA-approved protein kinases contain the pyrimidine moiety while six drugs contain quinazoline and eight drugs contain pyrazole. In other words\, about 50% of approved protein kinase inhibitors contain one of pyrimidine\, pyrazole or quinazoline\, highlighting the lack of progress in using other regions of the chemical space to drug protein kinases. The Sintim group\, integrating computational and experimental workflows\, has identified a few novel chemotypes that inhibit disease-associated protein kinases (such as FLT3\, RET\, CDKs\, Haspin) with sub-nanomolar IC50 values. Some of these new KI are long residence time (hours) inhibitors and have shown impressive efficacies in animal models of various cancers. Two of such compounds are currently undergoing toxicology studies to determine safe dosing regimens for potential phase 1 clinical trials against drug-resistant FLT3 (F691L and D835V/Y)-driven AML and RET (solvent front mutations)-driven lung cancers
URL:https://www.chemistry.ucla.edu/seminars/special-organic-colloquium-prof-herman-o-sintim/
CATEGORIES:Organic Colloquium,Seminars
END:VEVENT
END:VCALENDAR